BETHEL, Conn., Nov. 1, 2007 (PRIME NEWSWIRE) -- Aduromed Industries Inc. (OTCBB:ADRM), a leading manufacturer of medical waste treatment systems, today announced the sale of its MC4 System to Franklin Square Hospital Center of Baltimore, Maryland. This MedClean(r) Series System is configured to annually treat up to 1.6 million pounds of medical and other related institutional waste.
In addition to medical waste, the system will allow Franklin Square to destroy its confidential documents in full compliance with HIPAA regulations, avoiding costly outsourcing and further enhancing the return on the hospital's investment. The installed system will replace an existing incinerator. It will commence operation in 2008 upon completion of a major building expansion on the Franklin Square campus.
"Aduromed continues to demonstrate that its superior technology is accepted by healthcare providers throughout the U.S.," said Damien R. Tanaka, CEO and President of Aduromed. "Our family of MedClean System users continues to grow. The installation at this well-respected facility in Maryland is a significant addition to our existing customer base. We appreciate Franklin Square's selection of Aduromed's technology following their analysis of competitive alternatives and their confidence that our system will afford them efficacious, cost-efficient, safe, and environmentally-friendly treatment of their medical waste."
About Aduromed Corporation
Aduromed Industries, Inc., through its wholly-owned subsidiary, Aduromed Corporation, is one of the largest modern day providers of systems for the onsite disposal of medical waste that incorporates the design, installation and servicing of turnkey systems to treat infectious regulated medical waste (RMW). ADRM provides proprietary equipment and systems for efficient, safe, cost effective and legally compliant alternative solutions to incineration or off-site hauling of RMW, as well as to other treatment technologies and methodologies. With a strong base of suppliers and clients ADRM is positioned for significant growth within the medical waste industry.
Aduromed's MedClean Series System treats and processes all forms of RMW, sterilizing the waste prior to rendering it unrecognizable. Through the use of a unique and proprietary dual-stage shredding machine, this System converts such waste into safe solid waste (SSW) for disposal into a normal landfill. The System is part of Aduromed's MedClean Program, which incorporates collection, transportation and processing of medical waste on site, and eliminates any manual handling or transfer of the medical waste until its conversion into SSW, thereby protecting the operator and limiting liability for the institutions using the Program. The Program provides the further benefit of eliminating the transportation of RMW over public roadways. The unique design and arrangement of the System's components make it the smallest footprint within an industry where real estate is at a premium. Each MedClean Series System installation is sized appropriately to ensure ample capacity to treat and process medical waste efficiently and effectively.
The current U.S. medical waste market is estimated to be $3 billion. Further information on Aduromed can be found at www.aduromed.com and in filings with the Securities and Exchange Commission found at www.sec.gov.
Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-KSB for the year ended December 31, 2006, filed with the SEC on March 30, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.